Corporate Banner
Satellite Banner
Proteomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

In-vivo Study Shows CK1D Inhibitors Improve Cognition in Alzheimer’s Model

Published: Thursday, January 03, 2013
Last Updated: Thursday, January 03, 2013
Bookmark and Share
Proteome Sciences study shows improved cognition using its compounds.

Proteome Sciences has announced that the in-vivo study of its proprietary CK1D inhibitor programme in Alzheimer’s disease was completed as anticipated in December 2012.

Having already confirmed earlier in the year that CK1D inhibitors block tau phosphorylation in cell lines in an in-vitro study, Proteome Sciences has announced that both of its lead compounds for CK1D have demonstrated improved cognitive function in the current study.

These results provide important in-vivo proof of principle and demonstrate the efficacy of our compounds.

The next phase will start immediately in January to undertake and complete a comprehensive assessment of biological indicators and drug levels in various tissues.

Dr. Ian Pike, Chief Operating Officer commented :- "These results further validate PS Biomarker Services’ proteomic approach in discovery of new drug targets in challenging diseases. By diligently following the tau hypothesis of Alzheimer's disease we have been able to develop exciting new therapeutic strategies that are increasingly recognized by the scientific community as important components of the fight to halt Alzheimer's disease progression. We believe that inhibiting CK1D will be an important component in treatment of AD and we will concentrate on rapidly developing these assets."

Christopher Pearce, CEO said :- “Our goal was to deliver in-vivo proof of principle for CK1D in Alzheimer’s disease. We are delighted that this has been successfully achieved in 2012. These results are most timely as major pharmaceutical companies and academia have increasingly been switching attention to the importance of tau tangles in combination with amyloid aggregation in Alzheimer’s. In light of UK Government's recent commitment to fully fund NHS access to novel treatments for AD we believe there is significant potential for CK1D inhibitors to positively affect the lives of sufferers and their carers. We will continue to push our CK1D programme forward and will actively engage with the pharmaceutical industry to bring our compounds to clinical trials as soon as possible”.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Deep Protein Profiling Key
Company has encouraged by two recent reports that emphasise the importance of protein profiling to improve outcomes in cancer treatment.
Wednesday, April 06, 2016
Proteome Sciences Extends its Reach Through Collaboration with MedBiomix Partners
Collaborative network alliance provide advanced data-driven solutions to integrate and make better use of protein expression data.
Wednesday, February 04, 2015
Appointment of Non-Executive Director
Company Board announces the appointment of Mr. Martin Diggle.
Friday, October 17, 2014
Proteome Sciences Signs $2m Contract with Genting TauRx Diagnostic Centre
Contract to develop diagnostic panels to detect Alzheimer’s disease and monitor treatment efficacy.
Tuesday, September 30, 2014
Science and Technology Award for TMT at HUPO World Congress
TMT® chemical tags, distributed through Thermo Scientific, have become the global market leader.
Monday, September 15, 2014
Breakthrough Profiling Technology to Improve Cancer Treatment on a Personalized Basis
New research paper published in the peer reviewed journal PLOS ONE.
Saturday, April 12, 2014
Proteome Sciences Announces £5M Placing
Company conditionally places 17,857,143 new ordinary shares.
Monday, February 24, 2014
Proteome Sciences Appoints Director of Personalised Medicine
Proteome Sciences announces it has appointed Dr Chee Gee See as Director of Personalised Medicine with immediate effect.
Wednesday, October 30, 2013
Proteome Sciences to Develop Cancer Pathway Profiling Assays
New MS3 TMT® mass spectrometry technique to determine relative quantitation of proteins in multiple samples simultaneously.
Monday, June 17, 2013
Stroke Blood Test That Could Increase Use of Most Effective Treatment Five-Fold
UNIGE in collaboration with Proteome Sciences describe a simple blood test.
Friday, September 21, 2012
CK1D Development Update
Proteome Sciences has achieved further milestones in the development of inhibitors of the casein kinase 1 delta (CK1d) target in its Alzheimer's disease portfolio.
Tuesday, August 07, 2012
Stroke Biomarker License to Randox
Stroke biomarker to develop and produce diagnostic tests that could increase by fivefold the number of patients treated for stroke.
Friday, April 06, 2012
Completion of Alzheimer’s Plasma Biomarker Study
The preliminary results demonstrate significant diagnostic and prognostic utilities.
Wednesday, April 04, 2012
Scientific News
Oxygen Can Impair Cancer Immunotherapy
Researchers have identified a mechanism within the lungs where anticancer immune resposnse is inhibited.
Symmetry is Key to Collagen
Researchers describe how symmetry may be the key to growing collagen fibres outside the body.
Breakthrough in GPCR Understanding
Integral Molecular announces breakthrough in understanding the functionality of GPCRs, the largest class of drug targets in human disease.
Designing Ultrasound Tools with Lego-Like Proteins
Study outlines how ultrasound technology can be used for imaging in conjuction with protein engineering.
Enzyme that Triggers Cell Demise in ALS Identified
Scientists from Harvard have identified a key instigator of nerve cell damage in people with amyotrophic lateral sclerosis (ALS).
Molecular Alarm Clock Wakes Resting Ovules
Study of fruit flies yields discovery of a molecular "alarm clock" that activates resting ovules.
Catching Proteins in the Act
Scientists can now observe light activated processes in proteins through the use of free-electron x-ray lasers.
Proteins Preserve Vital Genetic Data
Research has shown how two key proteins bring about the oragnization of chromosomes and our genome.
Signaling Molecule Regulates Release of the Hunger Hormone Ghrelin
Researchers at UT Southwestern have identified that the blocking release of the hormone ghrelin may mediate low blood sugar effect in children taking beta blockers.
Telomere Replenishment in Real Time
Researchers have visualised the process of telomere attachment to chromosomes through single-molecule imaging.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!